Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, April 07, 2010

Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations



CONCLUSIONS: In overall performance, the PAT is at least comparable to the Myriad II and Penn II models in screening women appropriate for genetic referral. Simplicity and identification of families with non-BRCA hereditary BC syndromes suggest that the PAT is better suited for BC risk screening.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.